Full-spectrum investigational medicinal products
Our products
YCJ-01
Antiepileptic
YCJ-01 is an investigational drug to treat refractory epilepsy within the Tuberous Sclerosis Complex (TSC). The drug will soon be tested for efficacy in a clinical trial authorised by the AEMPS (The Spanish Agency for Medicines and Health Products).
YCJ-02
Antispastic / Analgesic
YCJ-02 is a drug currently under development to treat spasticity and neuropathic pain in leukodystrophies.
A clinical trial is planned as soon as the development of the investigational drug is completed.
Medicines in development
Oils4cure was created with the mission to develop effective medicines to treat the symptomatology of patients with rare diseases.
We are the architects and owners of the development of the process from start to finish, using the two varieties registered and authorised by the AEMPS (Spanish Agency for Medicines and Health Products) as the starting material.
We aim to find an effective drug to alleviate Refractory Epilepsy one of the most serious symptoms in the pathology of Tuberous Sclerosis (T.S.), and the symptoms of neuropathic pain and spasticity, ataxia… in Leukodystrophies.
Affected by refractory epilepsy.
Cannabis use is set to have a major impact on the pharmaceutical sector in the coming years thanks to the beneficial characteristics of its main cannabinoids CBD/THC.